» Articles » PMID: 39832406

Reactive EEG Biomarkers for Diagnosis and Prognosis of Alzheimer's Disease and Mild Cognitive Impairment

Overview
Date 2025 Jan 20
PMID 39832406
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative condition characterized by progressive cognitive decline with currently no effective treatment available. One of the most critical areas in AD research is the identification of reliable biomarkers, which are essential for accurate diagnosis, prognostic assessment, and the development of targeted therapies. In this study, we introduce two novel reactive EEG (rEEG) biomarkers aimed at enhancing the diagnosis of AD and mild cognitive impairment (MCI). These biomarkers, previously unexplored in the literature, offer new insights into differentiating between various cognitive states. The first biomarker demonstrates a significant ability to distinguish between AD patients and normal controls (NC), while also effectively distinguishing MCI patients from NC. The second biomarker is designed to identify a subset of AD patients exhibiting hyperconductivity or hyperactivity, characterized by distinctive neural electrical patterns. A cohort of 90 elderly participants (mean age 76.63 ± 6.08 years) was recruited, including 30 AD patients, 30 individuals with MCI, and 30 NC subjects. Psychiatric diagnoses of participants were made by qualified professionals at Daejeon St. Mary's Hospital, The Catholic University of Korea, utilizing comprehensive neuropsychological assessments. Notably, the rEEG biomarkers achieved accuracies of 95%, 95%, and 98% in distinguishing between AD and NC, AD and MCI, and MCI and NC groups, respectively. These results underscore the potential of rEEG as a highly accurate and reliable diagnostic tool for cognitive impairments, including AD and MCI.

References
1.
Sola J, Adler A, Santos A, Tusman G, Suarez Sipmann F, Bohm S . Non-invasive monitoring of central blood pressure by electrical impedance tomography: first experimental evidence. Med Biol Eng Comput. 2011; 49(4):409-15. DOI: 10.1007/s11517-011-0753-z. View

2.
Busche M, Kekus M, Adelsberger H, Noda T, Forstl H, Nelken I . Rescue of long-range circuit dysfunction in Alzheimer's disease models. Nat Neurosci. 2015; 18(11):1623-30. DOI: 10.1038/nn.4137. View

3.
Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987; 149(2):351-6. DOI: 10.2214/ajr.149.2.351. View

4.
Barbour B . Analysis of Claims that the Brain Extracellular Impedance Is High and Non-resistive. Biophys J. 2017; 113(7):1636-1638. PMC: 5627393. DOI: 10.1016/j.bpj.2017.05.054. View

5.
Hector A, Brouillette J . Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease. Front Mol Neurosci. 2021; 13:600084. PMC: 7817907. DOI: 10.3389/fnmol.2020.600084. View